Study of Serum Copeptin Level as a Novel Biomarker Predicting Liver Fibrosis in Hepatitis C-Infected PatientEmad Ahmad Awad Hussein, Khaled Abdulhameed Mohammed, Hagar Ahmed Ahmed Elessawy, Hussein Mohamed Hussein El- Sayes
- General Medicine
There are many factors that can lead to liver cirrhosis and portal hypertension, which include viral hepatitis, alcohol abuse, sclerosing cholangitis, and common inborn errors of metabolism that include Wilson disease, hemochromatosis, and alpha-1 antitrypsin deficiency. Viral hepatitis accounts for the majority of chronic liver diseases (CLDs) worldwide, CLD can progress to significant liver fibrosis or cirrhosis.
To evaluate copeptin as a novel marker in predecting liver fibrosis in HCV infected patient.
Patients and Methods
60 patients were recruited from the Department of Internal Medicine and the Outpatient Clinic of Ain Shams University hospital in the period between June 2020 and June 2021.
We found in our study that copeptin level at cut-off value 6.97 pmol/l with 93.3% sensitivity, 80% specificity,+ve pv82.4, _ve pv 92.3 and accuracy 73% to differentiate cirrhosis (F4) from fibrosis (F3) this was in agreement with Khaled et al., who found that copeptin at cut-off 7 pmol/l with 78%sensitivity, 85%specificity, +ve pv 83 and _ve pv 81 to differentiate compensated cirrhosis group from decompensated cirrhosis groups.
We studied serum level of copeptin in 60 HCV- patients classified in to two group aaccording to fibroscan score as discussed before. concluded for significant increase of serum copeptin in liver cirrhosis group than other fibrosis groups, Also concluded for Copeptin concentrations increase along with the severity of liver disease as well as some of its complication.